UM

Browse/Search Results:  1-2 of 2 Help

Selected(0)Clear Items/Page:    Sort:
Artesunate, a new antimalarial clinical drug, exhibits potent anti-AML activity by targeting the ROS/Bim and TFRC/Fe2+ pathways Journal article
Liu, Yi, Li, Han, Luo, Zhihong, Yu, You, Yang, Jingzhao, Zhang, Min, Law, Betty Yuen Kwan, Huang, Zan, Li, Wenhua. Artesunate, a new antimalarial clinical drug, exhibits potent anti-AML activity by targeting the ROS/Bim and TFRC/Fe2+ pathways[J]. British Journal of Pharmacology, 2022, 180(6), 701-720.
Authors:  Liu, Yi;  Li, Han;  Luo, Zhihong;  Yu, You;  Yang, Jingzhao; et al.
Favorite | TC[WOS]:4 TC[Scopus]:4  IF:6.8/7.4 | Submit date:2023/01/30
Acute Myeloid Leukaemia  Apoptosis  Artesunate  Bim  Differentiation  Tfrc  
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival among Patients with Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial Journal article
Wang, Xi, Wang, Shu Sen, Huang, Heng, Cai, Li, Zhao, Li, Peng, Rou Jun, Lin, Ying, Tang, Jun, Zeng, Jian, Zhang, Le Hong, Ke, Yong Li, Wang, Xian Ming, Liu, Xin Mei, Chen, Qian Jun, Zhang, An Qin, Xu, Fei, Bi, Xi Wen, Huang, Jia Jia, Li, Ji Bin, Pang, Dan Mei, Xue, Cong, Shi, Yan Xia, He, Zhen Yu, Lin, Huan Xin, An, Xin, Xia, Wen, Cao, Ye, Guo, Ying, Su, Yan Hong, Hua, Xin, Wang, Xin Yue, Hong, Ruo Xi, Jiang, Kui Kui, Song, Chen Ge, Huang, Zhang Zan, Shi, Wei, Zhong, Yong Yi, Yuan, Zhong Yu. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival among Patients with Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial[J]. JAMA - Journal of the American Medical Association, 2021, 325(1), 50-58.
Authors:  Wang, Xi;  Wang, Shu Sen;  Huang, Heng;  Cai, Li;  Zhao, Li; et al.
Favorite | TC[WOS]:146 TC[Scopus]:132  IF:63.1/66.8 | Submit date:2021/12/07